VivoSeq
Musculoskeletal

Ankylosing Spondylitis

97

Pipeline Programs↗

12

Active Trials↗

40

Companies Involved↗

Ankylosing Spondylitis is a moderately active landscape with 97 programs across 40 companies. The most active players are Asia Cell Therapeutics (Shanghai) Co., Ltd., Bristol-Myers Squibb, AbbVie. 25 therapies are approved with 30 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

69/100

Pipeline Velocity

15/100

Mech. Concentration

14/100

Completion Rate

88/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Asia Cell Therapeutics (Shanghai) Co., Ltd.

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2AbbVie logo

AbbVie

2 programs

Phase 2L

Lynk Pharmaceuticals Co., Ltd

1 program

Phase 2G

Ganzhou Hemay Pharmaceutical Co., Ltd

1 program

Phase 2Amgen logo

Amgen

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

76%

Small molecule

80 of 105 classified programs — the dominant modality here.

24%ALL OTHERSMonoclonal antibody1817%Protein / enzyme44%Cell therapy33%

Small molecule leads; the ring shows all 105 classified programs, each share of the total. Modality classified for 100% of 115 pipeline programs.

Analysis

Trial Status

174

clinical trials

Completed121 · 70%
Unknown status25 · 14%
Terminated11 · 6%
Recruiting6 · 3%
Withdrawn5 · 3%
Active, not recruiting4 · 2%
Other2 · 1%

Clinical Trials

Trial Activity

174 trials

A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis
Recruiting·LLynk Pharmaceuticals Co., Ltd·Phase 3·NCT07237568·352 enrolled
A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)
Recruiting·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 3·NCT07261644·500 enrolled
Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
Recruiting·Novartis logoNovartis·N/A·NCT06905288·70 enrolled
Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
Recruiting·JJiangsu vcare pharmaceutical technology co., LTD·Phase 3·NCT07172360·420 enrolled
A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
Recruiting·TTongji Hospital·Phase 4·NCT05303285·100 enrolled
SUNSHINE/SUNRISE: Bimekizumab in Axial SpA
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT04636346·400 enrolled
Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)
Active, not recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 3·NCT05861102·265 enrolled
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Active, not recruiting·UCB logoUCB·Phase 3·NCT04436640·508 enrolled
COAST-Y: Ixekizumab Long-Term in Axial SpA
Active, not recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT06500001·600 enrolled
SPIRIT-P3: Ixekizumab in Axial SpA
Active, not recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT05300005·490 enrolled
Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis
Not yet recruiting·TThe Affiliated Hospital Of Guizhou Medical University·Phase 4·NCT06833112·10 enrolled
Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Ankylosing Spondylitis
Not yet recruiting·AAsia Cell Therapeutics (Shanghai) Co., Ltd.·Phase 1·NCT05962762·9 enrolled
A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)
Completed·Merck & Co. logoMerck & Co.·N/A·NCT01313858·1,613 enrolled
Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
Completed·AbbVie logoAbbVie·N/A·NCT01768858·96 enrolled
Efficacy and Safety of Risedronate (Actonel), a Third Generation Bisphosphonate in Patients With Ankylosing Spondylitis: a Phase 2 Pilot Study
Completed·UUniversity of Zurich·Phase 2·NCT01038011
Page 1 of 12

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)